Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 17Myelodysplastic Syndromes 8Recurrence 2Leukemia, Myelomonocytic, Chronic 2Triple Negative Breast Neoplasms 1Spinocerebellar Degenerations 1Sarcoma 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasm, Residual 1Melanoma 1Medulloblastoma 1Lymphoma 1Leukemia 1Graft vs Host Disease 1Ependymoma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Temozolomide 6Methotrexate 5Radiotherapy 4Carboplatin 4Magnetic Resonance Spectroscopy 3Vincristine 2Thiotepa 2Specimen Handling 2Procarbazine 2Nivolumab 2Filgrastim 2Carmustine 2Bevacizumab 2sodium thiosulfate 1selinexor 1sargramostim 1motexafin gadolinium 1irinotecan sucrosofate 1infigratinib 1fluoroacetic acid 1Trastuzumab 1Topotecan 1Standard of Care 1Rituximab 1Radiation 1RG7388 1Psychiatric Rehabilitation 1Practice Guidelines as Topic 1Peripheral Blood Stem Cell Transplantation 1Oxaloacetic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Central Nervous System Neoplasms × Azacitidine × Clear all
NCT06466798 2026-01-08

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

The University of Texas Health Science Center, Houston

Phase 1 Withdrawn
CNS

Ependymoma, Medulloblastoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡